After Listing Delayed, Collategene Expected to Reach Market by Year-End: AnGes Founder

AnGes Founder and Osaka University Professor Ryuichi Morishita AnGes’ HGF gene therapy Collategene (beperminogene perplasmid) is expected to be launched in Japan by the end of the year after it skipped reimbursement listing in May, the founder of the Osaka-based...read more